Biotechnology Analyst Hsieh provides a preview of the upcoming first-in-human data of VK2735, the dual GLP-1/GIP agonist from Viking Therapeutics on an Analyst/Industry conference call to be held on February 24 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- William Blair biotech analysts to hold an analyst/industry conference call
- Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Viking Therapeutics reports Q4 EPS (26c), consensus (23c)